- AYMES Products
- Paediatric ONS
- AYMES Academy
- Contact us
Ravneet Phalora, Senior Specialist Oncology Dietitian and
Annina Whipp, Registered Dietitian
By the end of this article, you should be able to:
Optimal nutritional status promotes the best cancer treatment tolerance and outcomes. It therefore plays a critical role within cancer pathways. Evidence supports screening and nutritional support to commence at diagnosis, however malnutrition remains under-recognised throughout clinical practice.¹
Malnutrition has been found to affect up to 75% of cancer patients and can be a consequence of the tumour itself, or as a result of treatment side-effects.² Tumour site is a determinant of malnutrition, with pancreatic, gastrointestinal and head and neck cancers having the highest prevalence.³ Chemotherapy induced nausea, vomiting, diarrhoea and dysphagia can further exacerbate malnutrition and are associated with increased morbidity and mortality.³ It is estimated that between 10-20% of cancer patients die because of malnutrition, rather than the tumour itself.¹
Sarcopenia is another nutrition-related complication, classified as a muscle disease adversely affecting existing muscle quantity, strength and function.⁴ Low muscle mass is found in more than half of patients at diagnosis, despite only 10% being classified as underweight.⁵ Low muscle mass occurs independently of body weight and is associated with cancer progression. Maintaining muscle mass via nutritional therapy can improve outcomes and should be offered alongside antineoplastic treatments.⁵
Dietetic support has an integral role within cancer pathways. There are several interventions in place to help minimise the effects of poor nutritional status.
Nutrition risk screening
Recent European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines suggest that nutritional risk screening (NRS) is performed at the time of diagnosis and undertaken regularly throughout treatment to identify changes to nutritional status.¹ NRS evaluates a patient’s nutritional intake, body mass index (BMI) and weight change to evaluate the risk of malnutrition. Several validated NRS tools exist, including the Malnutrition Universal Screening Tool (MUST), however the Patient-Generated Subjective Global Assessment (PG-SGA) is widely used in clinical practice to assess the nutritional status of cancer patients.⁶ If nutritional risk is identified, an objective and quantitative assessment of nutritional intake and muscle mass should be performed.¹
ESPEN suggests that dietetic intervention at diagnosis should be offered to cancer patients in high-risk groups to optimise nutritional status.¹ Prehabilitation provides multimodal therapies (e.g., exercise, psychological and nutrition support) prior to treatment, which has been found to improve treatment outcomes and long-term health. The nutrition component of a prehabilitation programme should work alongside the exercise intervention to support muscle mass and strength maintenance.⁷ However, treatment side effects (e.g., fatigue, nausea) can significantly inhibit compliance with the programme.
Dietetic counselling commences during the prehabilitation phase of treatment to provide an individualised treatment plan which helps patients to:
Dietary interventions should provide nutritional advice alongside medical management to relieve symptoms and encourage adequate intake.⁷ A food first approach is the preferred way to maintain nutritional status.¹,⁸ This is achieved through a high-protein, high-energy diet consisting of regular meals, snacks, nourishing drinks, and food fortification (e.g., the addition of full fat milk, olive oil, cream and cheese to meals). If patients are unable to meet nutritional requirements via diet, oral nutritional supplements (ONS) are used to increase energy and protein intake.¹ In patients with impaired absorption or tolerance of food, enteral nutrition (via nasogastric or gastrostomy feeding tubes) can be trialled. Parenteral nutrition (intravenous administration of nutrition) is indicated in cases of severe intestinal insufficiency.¹ For the purpose of this article, the focus is on oral nutritional support.
The recommended energy requirements for cancer patients are similar to healthy individuals (25-30 kcals/kg/day).¹ There is some debate concerning what is considered an adequate protein intake. Current guidance recommends 1 to 1.5 g/kg/day of protein, however some studies have suggested a higher protein intake (>1.5 g/kg/day) can maintain or improve muscle mass.¹,⁵ Raised protein requirements alongside reduced oral intake secondary to treatment side-effects, emphasises the need for nutrition support from dietitians
Oral nutritional supplements
Oral nutritional supplements are a range of high-energy drinks which are indicated if patients meet less than 50% of their nutritional requirements for more than one week.¹
To enhance ONS compliance, it is important that the following are considered:
There is a high prevalence of malnutrition among cancer patients which increases the risk of morbidity and mortality.²,³ There is strong clinical evidence that specialist dietetic input as part of a prehabilitation programme, and throughout a patient's cancer journey, can optimise nutritional status and help to improve long-term patient outcomes.